New PBS listings from 1 March will include the first immunotherapy (atezolizumab) subsidised for small cell lung cancer (SCLC) and durvalumab for NSCLC. Atezolizumab (Tecentriq, Roche) will be have its PBS listing expanded to include first-line treatment of patients with extensive-stage small cell lung cancer (SCLC) in combination with a platinum-based chemotherapy and etoposide. Around ...
SCLC patients to gain PBS access to immunotherapy
19 Feb 2020